Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalnews2026-05-14T11:00:17+00:00May 14th, 2026|Endpoints News|
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclextanews2026-05-14T10:31:51+00:00May 14th, 2026|Endpoints News|
After an apparent cure, a gene editing company struggles to repeat the magicnews2026-05-13T18:50:53+00:00May 13th, 2026|Endpoints News|
Takeda to target 4,500 jobs as incoming CEO continues restructuringnews2026-05-13T18:36:06+00:00May 13th, 2026|Endpoints News|
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demandnews2026-05-13T17:46:51+00:00May 13th, 2026|Endpoints News|
Abeona pivots to T cells; AstraZeneca’s rare disease drug passes Phase 3news2026-05-13T15:36:52+00:00May 13th, 2026|Endpoints News|
Post-Hoc: Why FDA Commissioner Marty Makary was oustednews2026-05-13T14:46:37+00:00May 13th, 2026|Endpoints News|
Behind Galapagos’ transformation into Lakefront Biotherapeuticsnews2026-05-13T13:30:48+00:00May 13th, 2026|Endpoints News|
Tessera reveals strongest data yet for in vivo sickle cell therapynews2026-05-13T12:00:56+00:00May 13th, 2026|Endpoints News|
Merck KGaA’s clients are stockpiling due to Iran war, supporting guidance boostnews2026-05-13T11:01:36+00:00May 13th, 2026|Endpoints News|
